Canopy Growth is planning another reverse stock split less than two years after its previous one in December 2023. The cannabis company's shares have fallen roughly 80% since that split and are now trading below $1, risking delisting from major exchanges. The shareholder vote on the proposed reverse split is scheduled for 25 September. Major exchanges typically require companies to maintain share prices above $1 to remain listed. Despite the stock's struggles, Canopy Growth reported 13% sales growth across all divisions in the first quarter of fiscal 2027. The company's losses also decreased by 68% compared to the same period last year. Analysts note that reverse splits are rarely positive developments and usually indicate a company has limited options. The previous reverse split was followed by a nearly 50% decline before a brief rally.

Canopy Growth expands medical marijuana business into UK with four canadian-grown strains. Canopy Growth announced Tuesday that it is expanding its European medical marijuana business into the United Kingdom, with four Canadian-grown flower strains set to be distributed in the country. The products will be supplied to GROW Group U.K. Ltd., a British pharmaceutical company that imports, manufactures and distributes prescribed cannabis-based medicines across Europe. GROW Group will commercialize the strains in the U.K. under Canopy Growth's Spectrum Therapeutics medical brand. Canopy Growth said the launch marks the first introduction of its portfolio products into the U.K. market. "Expanding availability of our products into the UK is another step in growing our European medical cannabis business and broadening the international reach of our Canadian-grown flower," said Canopy Growth Chief Executive Officer Luc Mongeau. Mongeau said the company sees additional opportunities to expand in European medical markets as demand grows and Canopy increases its ability to supply products meeting European manufacturing standards. The expansion follows the August renewal of European Union Good Manufacturing Practice (EU GMP) certification for Canopy Growth's cultivation facility in Kincardine, Ontario. The certification allows marijuana grown at the facility to continue being supplied to medical markets across Europe. Canopy said in August that the Kincardine facility serves as a central part of its European supply chain, connecting Canadian-grown marijuana with European distribution operations through a second EU GMP-certified facility in Sankt Leon-Rot, Germany. The company has increasingly emphasized international medical marijuana markets as part of its broader business strategy. Canopy reported in August that international cannabis revenue increased 10% year-over-year during the first quarter of its 2027 fiscal year. The U.K. has allowed doctors to prescribe cannabis-based medicines under certain circumstances since 2018, with a growing private medical marijuana market developing in the years since.

Christelle Gedeon sells 13,344 shares of Canopy Growth (NASDAQ:CGC) stock. August 25, 2026 Key points. * Insider sale: Christelle Gedeon sold 13,344 Canopy Growth shares at an average price of $1.47, receiving $19,615.68. She retains 692,162 shares, a 1.89% reduction in her stake. * Stock performance: CGC recently traded at $1.07, with a market capitalization of approximately $480.75 million and a 52-week range of $0.84 to $2.38. * Mixed outlook: Canopy Growth beat quarterly earnings expectations and reported $142.62 million in revenue, but remained unprofitable. Analysts' average rating is "Hold," while institutional investors own only 3.33% of the company. * MarketBeat previews the top five stocks to own by September 1st. Canopy Growth Corporation (NASDAQ:CGC - Get Free Report) insider Christelle Gedeon sold 13,344 shares of the company's stock in a transaction on Monday, August 24th. The stock was sold at an average price of $1.47, for a total transaction of $19,615.68. Following the transaction, the insider owned 692,162 shares of the company's stock, valued at $1,017,478.14. This represents a 1.89% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Christelle Gedeon also recently made the following trade(s): * On Wednesday, June 17th, Christelle Gedeon sold 58,994 shares of Canopy Growth stock. The shares were sold at an average price of $0.97, for a total transaction of $57,224.18. Canopy Growth price performance. Shares of CGC stock traded up $0.02 on Tuesday, reaching $1.07. 3,133,336 shares of the company were exchanged, compared to its average volume of 8,714,521. The company has a market cap of $480.75 million, a price-to-earnings ratio of -2.38 and a beta of 0.81. The business has a 50-day moving average price of $0.96 and a 200 day moving average price of $1.03. The company has a debt-to-equity ratio of 0.31, a quick ratio of 2.39 and a current ratio of 3.04. Canopy Growth Corporation has a 1 year low of $0.84 and a 1 year high of $2.38. Canopy Growth (NASDAQ:CGC - Get Free Report) last issued its quarterly earnings results on Friday, August 7th. The company reported ($0.02) earnings per share for the quarter, beating analysts' consensus estimates of ($0.04) by $0.02. Canopy Growth had a negative net margin of 65.33% and a negative return on equity of 21.91%. The firm had revenue of $142.62 million for the quarter, compared to analyst estimates of $58.21 million. Equities research analysts forecast that Canopy Growth Corporation will post -0.1 earnings per share for the current fiscal year. Analysts set new price targets. CGC has been the subject of several recent research reports. Weiss Ratings downgraded Canopy Growth from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Wednesday, August 12th. Wall Street Zen raised shares of Canopy Growth from a "sell" rating to a "hold" rating in a research note on Saturday, August 8th. Two investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has an average rating of "Hold". Discover more Implementing Enterprise AI And Machine Learning Tools Analyzing Corporate Earnings Reports Institutional inflows and outflows. Several institutional investors have recently modified their holdings of CGC. Boothbay Fund Management LLC purchased a new stake in shares of Canopy Growth in the second quarter valued at about $30,000. Bank of Montreal Can boosted its holdings in Canopy Growth by 122.7% in the 4th quarter. Bank of Montreal Can now owns 25,174 shares of the company's stock valued at $29,000 after purchasing an additional 135,970 shares during the last quarter. PCG Wealth Advisors LLC purchased a new stake in shares of Canopy Growth in the 4th quarter valued at approximately $32,000. Sender Co & Partners Inc. purchased a new stake in shares of Canopy Growth in the 3rd quarter valued at approximately $63,000. Finally, WINTON GROUP Ltd purchased a new stake in shares of Canopy Growth in the 4th quarter valued at approximately $63,000. Hedge funds and other institutional investors own 3.33% of the company's stock. About Canopy Growth. Canopy Growth Corporation is a leading Canadian cannabis company engaged in the production, distribution and sale of both medical and recreational cannabis products. Headquartered in Smiths Falls, Ontario, the company cultivates a diversified portfolio of offerings that includes dried flower, pre-rolled joints, oils, softgel capsules and edibles. Canopy Growth also markets derivative products such as beverages and wellness formulations under a range of brands, aiming to serve both patient and adult-use markets. The company operates through multiple subsidiaries, including Tweed Inc, Spectrum Therapeutics and Tokyo Smoke, each targeting distinct consumer segments. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Continue following MarketBeat Before you consider Canopy Growth, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Canopy Growth wasn't on the list. While Canopy Growth currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys. Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you'll find 7 stocks that could play a major role in the next tech-driven market boom.